BOCA RATON, Fla., July 05, 2018 (GLOBE NEWSWIRE) -- The first highly purified and well-regulated pharmaceutical-grade curcumin, the most widely-studied plant-derived medicinal chemical in modern science, is now commercially available. Seeing a need for a purer, more effectively absorbing curcumin, Nutent Therapeutics developed, tested and launched VOLT03.

The active ingredient in the turmeric plant (curcuma longa), curcumin is a natural anti-inflammatory and antioxidant shown to improve brain function. It has also been shown to lower the risk of heart disease, help prevent and possibly aid in cancer treatment, provide relief for patients with arthritis and possibly help in the prevention and treatment of Alzheimer’s disease.

“Curcumin is proven to help people in so many ways, and we’ve given it the ability to have a better impact on health,” said Richard P. Becker Jr., R.Ph., M.B.A., CEO of Nutent Therapeutics. “Instead of what you may find sourced from bulk, food-grade powders with no pre-clinical or clinical data to support claims, VOLT03 is a powerful, pure and proven curcumin complex with corresponding data.”

Powerful

Evidence from numerous studies revealed curcumin does not dissolve well in water or in the stomach, leading to poor absorption and activity. Curcumin’s absorption in VOLT03 is improved through the complexation with gamma cyclodextrin, boosting solubility and ultimately bioavailability. It dissolves completely in water and reaches the bloodstream in high concentration (39 times more than common curcumin), therefore being more potent, less frequently dosed and available in smaller, easy-to-take capsules.

Pure

VOLT03’s pharmaceutical-grade quality makes it unique in the marketplace. Herbal dietary supplements often contain adulterated content, while VOLT03 is highly purified and regulated. It is manufactured according to the Current Good Manufacturing Practice (cGMP) regulations enforced by the FDA and has a “clean label:” meaning the only ingredients in its formulation are curcumin and pharmaceutical-grade (USP) cyclodextrin.

Proven

As rheumatologists, neurologists, naturopathic doctors, chiropractors, and other healthcare providers increasingly explore the benefits of curcumin, VOLT03 is the only curcumin product to demonstrate statistically significant anti-inflammatory properties, as compared with standard curcumin and a powerful prescription anti-inflammatory product (indomethacin). VOLT03 also proved its superior absorption to other brands in a human clinical study of bioavailability.

Bioavailability Study Background:

A gamma cyclodextrin curcumin complex was compared with a standardized unformulated curcumin extract and two commercially available formulations with reported increased bioavailability: a curcumin phytosome formulation (CSL), and a formulation of curcumin with essential oils of turmeric extracted from the rhizome (CEO). The cyclodextrin-complexed curcumin showed the highest plasma concentrations of curcumin, demethoxycurcumin, and total curcuminoids. The formulation also showed a statistically significant increase in relative bioavailability of total curcuminoids in comparison with standardized unformulated curcumin (39-fold), the CSL (4.5-fold), and the CEO (32-fold).

“My parents worked hard to put me through pharmacy school with the intent that I use my education to help people,” added Becker, with more than 20 years of experience in the pharmaceutical industry. “This is something I am very proud to help bring to the health community, and I hope it will increase vitality and relief for the many individuals understanding curcumin’s benefits and exploring it as part of their health plan.”

VOLT03 provides more than 80 mg of curcumin in each 500-mg capsule, dispensed in bottles of 60 capsules. It is now available to healthcare practitioners or directly to consumers. Learn more or purchase VOLT03 at www.nutenttherapeutics.com.

 

About Nutent Therapeutics

Nutent Therapeutics, Inc. (Nutent) is a South Florida-based nutraceutical provider, focused on clinical nutrition supported by pre-clinical or clinical data. Founded in January 2017, as a Delaware C-corporation, Nutent is based in Boca Raton, Fla., at Florida Atlantic University’s Research Park.

 

 

# # #

Attachment

Richard P. Becker Jr. R.Ph, MBA
Nutent Therapeutics, Inc.
(561) 208-3033
rbecker@nutenttherapeutics.com

Allison Aubuchon
Allison Aubuchon Communications, LLC
(850) 766-5255
communications@allisonaubuchon.com